Latest

New Luris publication: 'Aspects of Globalisation' 

Luris proudly presents the publication Aspects of Globalisation - Mobility, exchange and the development of multi-cultural states. The booklet features novel Leiden-based research on various aspects of globalisation, such as (ancient) migrations, multi-lingualism, multi-cultural states, trade routes and the spread of faiths.

Leiden University has an international - indeed, a global - reputation for excellent research in the Humanities. In  'Aspects of Globalisation' some of the University’s most promising scholars in the Humanities present their research into various aspects of the 'entangled' world. 

Connectivity, entangled worlds, globalisation. These are buzzwords that have dominated political and academic discourse over the past decade. But they matter, because they provide us with a framework to better conceptualise the ways in which societies are shaped, how they rise and fall, change and endure. On behalf of Leiden University, Luris hopes the studies presented in this publication may inspire the reader to rethink aspects of our own society. Aspects that strike us as familiar and ‘modern’, but that are as ancient as human society itself.

The booklet will be distributed at the Leiden University Dies Natalis on February 8 and will be made available to a wide audience. 

 

Luris’ Stefan de Jong awarded with Rubicon grant for research on university valorisation policies

January 19

Grant Advisor Stefan de Jong has been awarded a Rubicon grant for his research on the effects of university valorisation policies on the impact of academics. Many academics consider engagement with and impact on other individuals, groups and organisations in society inherent to their profession. Nevertheless, in recent decades governments, research funders and universities have introduced policies to increase impact of academics on society. Effects of these policies on research are well documented. Surprisingly, effects on impact itself have thus far received little attention. This project for the first time addresses this issue within the context of universities by answering the research question ‘how do internal impact policies affect societal engagement of academics?’.

Read more in the Leiden University news item.

Senior Grant Advisor Anna Groeninx retires

December 21

Luris Senior Grant Advisor Anna Groeninx is retiring this month. Anna is known throughout Leiden University as thé expert on European subsidies and her career in knowledge exchange spans more than three decades. To show our appreciation for her total commitment in supporting researchers obtaining grants and lobbying efforts, we organized the symposium 'Influencing H2020 and the next framework programme’ and a farewell reception for her on December 15th. Read an interview with Anna about her career here (in Dutch).

Early detection of hearing damage with on-line test

October 25

LUMC has, in collaboration with Amsterdam Medical Centre and Nationale Hoorstichting, developed an online test that can detect early stage hearing damage or loss. The test, that takes only five minutes and can be taken on a tablet or smartphone, is designed for people who work in a noisy environment.

The test has been developed by LUMC clinical physicist in audiology Jan de Laat. “We think it is important that our knowledge and innovative technology finds its way to society, and we gladly contribute to the prevention of hearing damage. That’s why we have worked together with Nationale Hoorstichting.” The test will be put on the market as ‘HearOn’.

Read the LUMC press release here (in Dutch). 

October 31: Read the Hearon blog 'van stichting naar start-up' here.

Luris change of address

As of August 22, Luris has relocated to a new location in Leiden's city centre.

Our new address:

Luris
Langegracht 70 (HUBspot)
2312 NV Leiden, The Netherlands

New phone number: +31-(0)71- 527 2558
E-mail: luris@luris.nl

More information

New: Luris 'H2020 Academy', a series of information meetings and events about EU Horizon 2020

Getting your research funded can be a struggle and writing proposals takes time and effort. The Luris Grant Development Team is aware of this: they spend 100% of their time helping researchers from Leiden University to get funded.

The Luris Grant Development team is organising 'H2020 Academy', a series of information meetings and events about Horizon 2020, the EU Framework Programme for Research and Innovation. Sign up for the H2020 Academy webinars and information meetings and take advantage of the team's experience and that of other experts in the university (successful candidates and evaluators) for the preparation of your proposal or other research support activity.

Check out the events here, or on the Leiden University website

Lift-off for UNIIQ

Luris' Tim de Jong is investment manager for the new proof-of-concept fund for entrepreneurs in the South Holland region

June 20

During the InnovationQuarter Annual Event, Startup Ambassador Neelie Kroes launched UNIIQ, which is a new investment fund in the South Holland region for the proof-of-concept phase of new technologies. UNIIQ is an initiative of Erasmus MC, Technical University Delft (TU Delft), Leiden University and the regional development agency InnovationQuarter. The fund assists entrepreneurs in South Holland to bring innovations faster to market. Luris' entrepreneurship advisor Tim de Jong is appointed as Leiden investment manager of the fund

Technology does not necessarily mean a business

The new fund amounts to € 22 million, and is available for entrepreneurs who want to bring promising new technologies to market. This is a difficult and risky phase. Technology can indeed be promising, but does not necessarily deliver business opportunities. UNIIQ helps entrepreneurs to create a business out of their innovation.
Read more about the launch of Uniiq.
Read more about the entrepreneurial programme of Leiden University and Leiden University Medical Center.

 

LUMC enters into research collaboration with Bellicum Pharmaceuticals for development of immunotherapies for cancer treatment

June 8

LUMC has signed a research collaboration agreement with American pharmaceutical company Bellicum. Over the next three years, LUMC will receive €2,5 million to develop immunotherapies for cancer treatment, with an initial focus on ovarian cancer. This new deal with Bellicum builds on an existing license and research agreement that was negotiated last year.
Read more.

New hay fever and pollen calendar available on LUMC website


May 26
LUMC’s departments of Pulmonology and the Quality Institute have signed an agreement with MeteoConsult about the new hay fever and pollen calendar they have developed. The six day calendar is available on the LUMC website: http://www.lumc.nl/hooikoortsverwachting

The new calendar has been developed during the past two years, by collecting symptoms of hay fever patients on a daily basis and combining these with the weather maps of MeteoConsult.
Read more.

Awards handed out for pitches at the Science meets Business Plan Competition 

May 3
Buxenus wins the Science meets Business Plan Competition 2016. Their presentation on the ‘lab in a box’-idea convinced the judges to grant them the €2000,- prize money. Buxenus will develop a small modular bioscientific laboratory with instrumentation that is tailored to automation and convenience.

Entrepreneurship Advisor Tim de Jong handed Niall Hodgins from NADES Solutions the Luris Audience award. NADES Solutions is a collaborative R&D company specialising in tailor making high performance natural solvents for pharmaceutical clients. 

Read more.


Collaboration with Canadian partner to market regenerative therapies

April 25

Leiden University Medical Center (LUMC) is continuously researching how the body heals itself. At the moment it is difficult to apply the scientific knowledge in new treatments so patients can profit from it. That is why LUMC’s professor Wim Fibbe (regenerative medicine), Paul Bilars (finances) and knowledge broker Mike Shaw from Luris have signed an agreement with the Canadian Centre for Commercialization of Regenerative Medicine (CCRM), who has already set up a business model in Canada for this purpose.

So called cellular therapies and tissue engineering are thought to be the future of medical science. Where traditional medicine fails, new models are necessary. For example, how do we teach the body to generate new blood vessels? Or, how can the body use its own cells to suppress  unwanted immune responses in case of, for instance, a kidney transplant? If that succeeds the patients could stop taking immunosuppressive medication. “With cellular therapies we try to enhance and imitate the natural repair processes of the body,” Professor Fibbe of the department of Immunohematology and Blood Transfusion explains.
Read more.